HONG KONG, Nov 25 (Reuters) - Pfizer Inc plans to expand its research and development operations in central and western China as it strengthens its biomedical infrastructure throughout the country, the company said on Wednesday.
Pfizer (China) Research and Development Co Ltd will team up with its Chinese partner, Wuhan National Bioindustry Base Construction and Management Office, to establish a new Pfizer R&D
“With plans to be a state-of-the-art facility the Wuhan center will be an integral part of Pfizer’s global R&D operations while being closely aligned with the Chinese government’s strategy on biopharmaceutical industry development in the region,” Allan Gabor, the company’s Regional President for North Asia, said in the statement.
Pfizer’s R&D operations in Wuhan will support global clinical drug development programs including Phase I-IV clinical trials and will utilize the resources of local staff and industry to develop research collaboration on drug innovation and development. https://www.reuters.com/article/pfizer-research-idCNHKG35399420091125
……………………………...........................
December 12, 2020
The last decade has seen a big expansion of Pfizer’s R&D footprint, facilities and capabilities, notably with the launch of China R &D Center Shanghai’s sister satellite R&D site in Wuhan in 2010. Currently the market leader among multinational biopharmaceutical companies in China, Pfizer has approximately 1,500 R&D colleagues working in China, with a degree in three key sites–namely Shanghai, Wuhan and Beijing. https://pharmacyinfoline.com/2020/12/12/pfizer-rd-facility-in-wuhan-china/
……………………………………
RESOLVED, that the Pfizer Board report to shareholders on the rationale for increasingly exporting the company’s animal experimentation to countries which have either non-existent or substandard animal welfare regulations and little or no enforcement. Further, the shareholders request that the report include information on the extent to which Pfizer requires—at a minimum—adherence to U.S.animal welfare standards at its facilities in foreign countries….The November 13, 2006 issue of Forbes magazine reported on Pfizer’s research in China, noting that the rationale for shifting animal testing to China is that “scientists are cheap, lab animals plentiful.” 1 http://www.pfizer.com/pfizer/subsites/corporate_citizenship/laboratory_u https://www.peta.org/wp-content/uploads/2021/06/2007-Pfizer-China-Resol.pdf
…………………………………………….
Hong Kong had purchased 7.5 million doses of a vaccine co-developed by U.S. pharmaceutical giant Pfizer and German vaccine maker BioNTech, Hong Kong's chief executive Carrie Lam and other government ministers said at a press conference. (Shanghai Fosun Pharma is a junior partner/shareholder with BioNTech)
At the event, government ministers repeatedly referred to the first vaccine as either Pfizer's or BioNTech’s.
https://fortune.com/2021/01/09/covid-vaccine-china-fosun-pfizer-biontech/
…………………………………..................
RP news wires
Pfizer Inc. on November 10, 2020 announced its global research and development network, marking an important step in implementing a new research and development (R&D) model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate.
Pfizer will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.; Groton, Conn.; Pearl River, N.Y.; La Jolla, Calif.; and Sandwich, United Kingdom. These research-oriented laboratories will be supplemented by specialized research capabilities, such as monoclonal antibody discovery in San Francisco, regenerative medicine work in Cambridge, U.K., and research and development activities in Shanghai (and Wuhan!), China.
“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” said Mikael Dolsten, president of BioTherapeutics Research & Development. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”
As part of the consolidation of research sites Pfizer will significantly reduce R&D activities at some of its sites. The company will move a number of functions from Collegeville, Pa.; Pearl River, N.Y.; and St. Louis to other locations and will discontinue R&D operations in Princeton, N.J.; Chazy, Rouses Point and Plattsburgh, N.Y.; Sanford and Research Triangle Park, N.C. and Gosport, Slough/Taplow, U.K. In addition Pfizer will consolidate R&D functions from its New London, Conn. site to its nearby research facility in Groton, Conn.
As a result of these changes, Pfizer will reduce its global R&D square footage by 35 percent. R&D activities will now be conducted at five main sites and nine specialized units around the world as compared with 20 R&D sites upon closing the acquisition of Wyeth on October 16, 2009. https://www.reliableplant.com/Read/21151/pfizer-to-close-6-r_d-sites,-reduce-activities-at-3-ors
…………………………………….
No comments:
Post a Comment